All Abuzz About CLL: Exploring Fixed-Duration Regimens and Cardiotoxicity Management

Target Audience
The intended audience for this activity are hematologic oncologists, hematologists, cardiologists, cardio‐oncologists, oncology advanced practice providers (NPs and PAs), oncology nurses, and other clinicians involved in the management of patients with CLL.

Statement of Need/Program Overview
The emergence of effective therapeutic combinations and the promise of fixed duration treatments holds the potential of improved long-term outcomes and quality of life for patients with chronic lymphocytic leukemia (CLL). While patients and providers alike have expressed a preference for time-limited therapies, a number of questions remain around clinical decision-making, including how to select patients for these therapies, and once on treatment, how to anticipate and address treatment-related adverse events.

Clinicians may be unaware of findings from late‐stage trials examining these combinations and may be hesitant to use certain therapies based on associated toxicity profiles. To help clarify misconceptions related to adverse events and ensure appropriate cardio‐oncology care when warranted, please join a panel of hematology/oncology and cardio-oncology experts to review the most up-to-date data on the care of CLL. Hear from a patient on their account of receiving upfront targeted therapy and their experience through decision-making. Panelists will share strategies to select the right upfront therapy as part of patient-centered care that maximizes long-term outcomes, ensures patient quality of life, and anticipates and manages side effects.

Educational Objectives
After completion of this activity, participants should be better able to:

Review the late-stage clinical data and ongoing trials evaluating fixed-duration regimens in CLL
Discuss patient preferences for fixed-duration therapy and strategies for patient counseling on appropriate treatment selection
Evaluate long-term and real-world data to maximize patient outcomes
Assess the current evidence-based guidelines and best practices for appropriate cardiovascular toxicity management across the cardio-oncology team
Promote patient-centered care through better understanding of real-world patient experiences